Minnesota SF4138 amends the insulin safety net program, defining covered insulin and establishing manufacturer registration fees.

Minnesota SF4138 amends the insulin safety net program by defining "covered insulin" as a drug containing insulin for treating diabetes, excluding insulin products with FDA-approved labels. The bill mandates manufacturers to provide eligible individuals with an eligibility statement for their patient assistance programs. It also establishes an annual registration fee of $100,000 for manufacturers, with exemptions for those with low gross revenue from insulin sales. The bill outlines procedures for accessing urgent-need insulin, including application forms and eligibility criteria.

Minnesota SF4138 amends the insulin safety net program, defining covered insulin and establishing manufacturer registration fees.

Minnesota SF4138 amends the insulin safety net program by defining "covered insulin" as a drug containing insulin for treating diabetes, excluding insulin products with FDA-approved labels. The bill mandates manufacturers to provide eligible individuals with an eligibility statement for their patient assistance programs. It also establishes an annual registration fee of $100,000 for manufacturers, with exemptions for those with low gross revenue from insulin sales. The bill outlines procedures for accessing urgent-need insulin, including application forms and eligibility criteria.